EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effects of Levodopa‐Carbidopa Intestinal Gel Compared with Optimized Medical Treatment on Nonmotor Symptoms in Advanced Parkinson’s Disease: INSIGHTS Study

Sun Ju Chung iD, Matilde Calopa iD, Maria G Ceravolo iD, Nicola Tambasco iD, Angelo Antonini iD, K Ray Chaudhuri iD, Weining Z Robieson iD, Olga Sánchez-Soliño iD, Cindy Zadikoff iD, Man Jin, Luigi M Barbato

Parkinson's Disease · 2022-01 · 2022 (1)

DOI: 10.1155/2022/1216975 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Parkinson's Disease, online erschienen am 04.11.2022. Verfasst von Sun Ju Chung und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nonmotor symptoms (NMS) are common in advanced Parkinson’s disease (APD) and reduce health‐related quality of life.

Objective

The aim of the study was to evaluate levodopa‐carbidopa intestinal gel (LCIG) versus optimized medical treatment (OMT) on NMS in APD.

Methods

INSIGHTS was a phase 3b, open‐label, randomized, multicenter study in patients with APD (LCIG or OMT, 26 weeks) (NCT02549092). Primary outcomes assessed were total NMS (NMS scale (NMSS) and PD sleep scale (PDSS‐2)). Key secondary outcomes included the Unified PD Rating Scale (UPDRS) Part II, Clinical Global Impression of Change (CGI‐C), and PD Questionnaire‐8 (PDQ‐8). Additional secondary measures of Patient Global Impression of Change (PGIC), King’s PD Pain Scale (KPPS), and Parkinson Anxiety Scale (PAS) also were evaluated. Finally, safety was assessed.

Results

Out of 89 patients randomized, 87 were included in the analysis (LCIG, n = 43; OMT, n = 44). There were no significant differences in NMSS or PDSS‐2 total score changes (baseline to Week 26) between LCIG and OMT; within‐group changes were significant for NMSS (LCIG, p < 0.001; OMT, p = 0.005) and PDSS‐2 (LCIG, p < 0.001; OMT, p < 0.001). Between‐group treatment differences were nominally significant for UPDRS Part II ( p = 0.006) and CGI‐C ( p < 0.001) at Week 26 in favor of LCIG; however, statistical significance could not be claimed in light of primary efficacy outcomes. PGIC (Week 26) and KPPS (Week 12) scores were nominally significantly reduced with LCIG versus OMT ( p < 0.001; p < 0.05). There were no significant differences in PDQ‐8 or PAS. Adverse events (AEs) were mostly mild to moderate; common serious AEs were pneumoperitoneum ( n = 2) and stoma‐site infection ( n = 2) (LCIG).

Conclusions

There were no significant differences between LCIG versus OMT in NMSS or PDSS‐2; both LCIG and OMT groups significantly improved from baseline. AEs were consistent with the known safety profile.

Autor:innen und Institutionen

  • Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Department of Neurology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Department of Experimental and Clinical Medicine, Neurorehabilitation Clinic, University Hospital of Ancona, Università Politecnica Delle Marche, Ancona, Italy.
  • Movement Disorders Center, Perugia General Hospital and University of Perugia, Perugia, Italy.
  • Movement Disorders Unit, Department of Neuroscience, University of Padua, Padua, Italy.
  • Institute of Psychiatry Psychology & Neuroscience, King's College and Parkinson Foundation International Centre of Excellence, King's College Hospital, Denmark Hill, London, UK.

ORCID-Profile: Sun Ju Chung, Matilde Calopa, Maria G Ceravolo, Nicola Tambasco, Angelo Antonini, K Ray Chaudhuri, Weining Z Robieson, Olga Sánchez-Soliño, Cindy Zadikoff

Förderung

  • AbbVie

Zitieren

APA

Chung, S. J., Calopa, M., Ceravolo, M. G., Tambasco, N., Antonini, A., Chaudhuri, K. R., Robieson, W. Z., Sánchez-Soliño, O., Zadikoff, C., Jin, M., & Barbato, L. M. (2022). Effects of Levodopa‐Carbidopa Intestinal Gel Compared with Optimized Medical Treatment on Nonmotor Symptoms in Advanced Parkinson’s Disease: INSIGHTS Study. Parkinson's Disease, 2022(1). https://doi.org/10.1155/2022/1216975

Vancouver

Chung SJ, Calopa M, Ceravolo MG, Tambasco N, Antonini A, Chaudhuri KR, et al. Effects of Levodopa‐Carbidopa Intestinal Gel Compared with Optimized Medical Treatment on Nonmotor Symptoms in Advanced Parkinson’s Disease: INSIGHTS Study. Parkinson's Disease. 2022;2022(1). doi:10.1155/2022/1216975

BibTeX
@article{Chung2022,
  author = {Chung, Sun Ju and Calopa, Matilde and Ceravolo, Maria G and Tambasco, Nicola and Antonini, Angelo and Chaudhuri, K Ray and Robieson, Weining Z and Sánchez-Soliño, Olga and Zadikoff, Cindy and Jin, Man and Barbato, Luigi M},
  title = {Effects of Levodopa‐Carbidopa Intestinal Gel Compared with Optimized Medical Treatment on Nonmotor Symptoms in Advanced Parkinson’s Disease: INSIGHTS Study},
  journal = {Parkinson's Disease},
  year = {2022},
  volume = {2022},
  number = {1},
  doi = {10.1155/2022/1216975}
}
Kostenlos starten →